General public
You are here
The PETAL Network
The Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (PETAL Network) is a network of 12 Clinical Centers (CC) and 1 Clinical Coordinating Center (CCC) funded by the National Heart, Lung, and Blood Institute (NHLBI) to develop and conduct randomized controlled clinical trials to prevent or treat, and/or improve the outcome of patients who have, or who are at risk for, Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Participating in Research
The 411 on being a research subject
Lungs 101
Get the basics on the respiratory system
Critical Illness
Terminology and other info explained
Primary studies
Ancillary studies
News
NHLBI PETAL Network ends Phase 3 sepsis trial early
PETAL Network study found no significant difference in 90-day mortality rates, nor safety concerns, after providing patients with one of two common treatment strategies
Major US Trial Closes Showing No Benefit for Hydroxychloroquine in COVID-19
June 20, 2020
On behalf of the PETAL Network, we are excited to share that two of the primary manuscripts have been published in the New England Journal of Medicine.